Phaseline

Targets › ALDH5A1

ALDH5A1 (Succinate-semialdehyde dehydrogenase, mitochondrial): drug programs, companies and trials

5 programs from 5 companies in 8 trials: 4 Phase 2, 3 Phase 1, 1 Phase 4; Oncology, Neurology, Immunology; next expected readout Dec 2026.

Catalyzes one step in the degradation of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). (UniProt, P51649)

Open in Phaseline: the race on ALDH5A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The First Affiliated Hospital of University of South ChinaValproate Sodium
Succinate semialdehyde dehydrogenase inhibitor
ALDH5A1Phase 4Epilepsy–
National Cancer Institute, NaplesValproic Acid
Succinate semialdehyde dehydrogenase inhibitor
ALDH5A1Phase 2Colorectal Cancer Metastatic; Adenocarcinoma of the PancreasDec 2026
Australasian Gastro-Intestinal Trials GroupValproate Sodium
Succinate semialdehyde dehydrogenase inhibitor
ALDH5A1Phase 2Metastatic Colorectal CancerJun 2027
Tanta UniversityValproate Sodium
Succinate semialdehyde dehydrogenase inhibitor
ALDH5A1Phase 2Temporomandibular Joint Internal Derangement (ADWR)–
Erasmus Medical CenterValproic Acid
Succinate semialdehyde dehydrogenase inhibitor
ALDH5A1Phase 1MelanomaOct 2027

Conditions

Melanoma (3) Metastatic Colorectal Cancer (1) Epilepsy (1) Colorectal Cancer Metastatic (1) Adenocarcinoma of the Pancreas (1) Temporomandibular Joint Internal Derangement (ADWR) (1)

Modalities

mixed (2), small molecule (2), other (1)

Companies

Australasian Gastro-Intestinal Trials Group (1) The First Affiliated Hospital of University of South China (1) Erasmus Medical Center (1) National Cancer Institute, Naples (1) Tanta University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.